It's not the performance or environmental cred that will get driving enthusiasts into EVs, it's this little-known piece of ...
Eisai Co., Ltd. announced today the company will present the latest findings from its Alzheimer's disease (AD) research, including lecanemab (brand name: LEQEMBI®), our anti-amyloid beta (A?) ...
Diranersen presentation will feature Phase 2 CELIA data in early Alzheimer's disease, including clinical, biomarker and safety results for Biogen's investigational tau-targeting ASO, following topline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results